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DISEASE-SPECIFIC STUDIES
CARDIOVASCULAR DISORDERS - Clinical Outcomes Studies
PCV1
ANGIOTENSIN RECEPTOR BLOCKERS AND THE RISK OF MYOCARDIAL
INFARCTION: NETWORK META-ANALYSIS AND PROBABILITY RANKING
Mazumder D, Arora A, Bhutani MK, Pathak P, Siddiqui MK
Heron Health Private Ltd., Chandigarh, India
OBJECTIVES: There is no head-to-head trial demonstrating the risk of myocardial
infarction (MI) across angiotensin receptor blockers (ARBs). This review assessed
the MI incidences associated with the use of ARBs through network meta-analyses
of randomised controlled trials (RCTs). METHODS: Embase® and MEDLINE® were
searched until June 2012 for RCTs assessing the safety of approved ARBs versus
active control/placebo. Studies were included based on a pre-specified protocol.
Data were extracted by two reviewers, with any discrepancy being reconciled by a
third, independent reviewer. A network meta-analysis was conducted and proba-
bility-based rank (P of being best) was generated using WinBUGS®. Subgroup anal-
yses by disease cohorts (hypertension, heart failure, and diabetes) were also
performed. RESULTS: Of the 3099 studies, 33 RCTs enrolling 143,205 patients were
included. Most studies reported data for up-titrated doses with continued back-
ground therapy. No significant differences were observed between ARBs and con-
trols in meta-analysis (relative risk [95% confidence interval]: 1.04 [0.99-1.10] vs.
active-control; 0.94 [0.83-1.07] vs. placebo). Network meta-analyses indicated no
significant difference among the ARBs. Subgroup analyses by disease cohorts
showed no significant difference between ARBs and active/placebo as well as
within ARBs. The probability of least MI incidence was highest with olmesartan 40
mg (P41%) followed by candesartan 16 mg (P19%), losartan 200 mg (P10%),
valsartan 80 mg (P9%), and candesartan 4 mg-8 mg (P4%-5%). Conversely, the
probability of least MI incidence was 1% with telmisartan 80 mg, irbesartan 300
mg, losartan 100 mg, valsartan 160 mg. A dose-risk assessment within ARBs re-
mained inconclusive due to limited data. CONCLUSIONS: ARBs did not differ sig-
nificantly from active control/placebo or from each other for the risk of MI. How-
ever, per probability-based ranking, olmesartan 40 mg may present the least risk of
MI. Limited data warranted careful interpretation of these results and further re-
search in this area using monotherapy data.
PCV2
COMPARATIVE EFFICACY AND SAFETY ANALYSIS OF ATRIAL FIBRILLAION
PATIENTS TREATED WITH DABIGATRAN IN RE-LY STUDY (CHADS 2 SCORE OF
3 OR GREATER ) VERSUS RIVAROXABAN IN ROCKET-AF
Rasty S1, Soliman W2, Taheri R3
1Roosevelt University, Buffalo Grove, IL, USA, 2Consultant, Fort lee, NJ, USA, 3West Coast
University, Los Angeles, CA, USA
OBJECTIVES: In this analysis we performed comparative efficacy and safety anal-
ysis of atrial fibrillation (AF) patients treated in RE-LY trial with ChadS2 score of 3 or
greater treated with Dabigatran (Dab) 150mg versus AF patients treated with Rivar-
oxaban (Riv) in ROCKET-AF study (Avg Chads2 score3.48). METHODS: Patient’s
baseline information and primary efficacy and safety outcomes data for both co-
horts were compared. WINPEPI (2011, version 11.15) epidemiological tool was used
to compare the event rates ( safety and efficacy) per 100 patient year (100PY).
RESULTS: Both groups were similar in age ( 73y), and consisted of roughly 40%
females. The average SBP and DBP were 130/80 vs 130.9 /76.3 mmHg in Riv vs Dab
patients. 82.5% of Riv compared to 69.8% of Dab had persistent AF. In Rocket –AF the
average Chads2 score was 3.38/ 0.94 with 87% of patients having score of 3.
Prior ASA intake was 36.3% in Riv vs 42.5% of Dab. 54.9% of Riv vs 55.2% of Dab had
previous Stroke/TIA/Systemic embolism. In Riv group 62.6%,92.3%, 40.4% and
16.6% had CHF, HTN, DM and MI compared to 48.3%, 91.5%,44.8% and 21.6% in the
Dab patients. For the primary end point of stroke or systemic embolism 1.7 events
in Riv vs 1.87 events in Dab occurred per 100PY (OR0.91; 95%CI0.62-1.32); for
safety end point of major bleed (any) 3.6 events in Riv vs 4.85 events in Dab occurred
per 100PY (OR0.73; 95%CI 0.57-0.93) and for Intracranial hemorrhage (ICH) 0.5
events in Riv vs 0.52 events in Dab occurred per 100 PY ( OR1; 95% CI 0.50-2.02).
CONCLUSIONS: This analysis of the published data suggests similar efficacy for
both agents when used in AF patients with higher risk for stroke (3), higher
major bleeding risks with Dab and similar rates for ICH with both agents.
PCV3
PREVALENCE, ASSOCIATED COMORBIDITIES AND TREATMENT PATTERNS
AMONG CHRONIC KIDNEY DISEASE PATIENTS: AN ANALYSIS USING UK GPRD
DATA
Jick S1, Hagberg KW1, O’Donoghue D2, Jameson K3, Ambegaonkar BM4
1Boston University School of Medicine, Lexington, MA, USA, 2Salford Royal NHS Foundation
Trust, Salford, UK, 3MSD Ltd., Hoddesdon, UK, 4Merck & Co. Inc., Whitehouse Station, NJ, USA
OBJECTIVES: To estimate the prevalence of stage 3-5 chronic kidney disease (CKD)
in 2010, evaluate the presence of comorbidities, and describe treatment among
CKD patients. METHODS: Data for patients with prevalent or incident CKD in 2010
(age  10 years at CKD diagnosis) were extracted from the UK General Practice
Research Database. Patients were identified using Read codes or eGFR values, and
those with cancer, hemolytic anemia, or sickle cell disease were excluded.
RESULTS: Among 3.16MM patients in GPRD, we identified 166,707 patients with
incident or prevalent stage 3-5 CKD in 2010 (5.3% of population). The majority of
patients were stage 3 (92.5%; stage 4  6.3%, stage 5  1.2%), female (62.1%) and,
92.6% were  60 years (92.6%; 99.9% were above 20 years). The most common
comorbidities were hypertension (64.7%), cardiovascular disease (37.1%), hyper-
cholesterolemia (25.2%), and diabetes (19.2%), each condition being significantly
more prevalent than in the general population (16.2%, 8.4%, 9%, and 5.5%, respec-
tively). With more advanced CKD, the presence of comorbidities increased: consid-
ering stage 3 to 5, the proportion of CKD patients with hypertension, CVD, hyper-
cholesterolaemia and diabetes increased from 63.7% to 80%, 36.2% to 43.5%, 25.1%
to 29.2%, and 18.4% to 33.1%, respectively. The proportion of CKD patients receiving
antihypertensive treatment or lipid-modifying therapy (LMT) also increased as
stage advanced: 76.5% in stage 3 to 79.8% in stage 5 were receiving antihypertensive
drugs, and 51.7% to 57.7% LMT. Statins were the most commonly used LMT agent (
89% for all these three stages). CONCLUSIONS: Stage 3 to 5 CKD affected 166,707
patients covered by GPRD in 2010 (prevalence rate  5.3%); most had stage 3 CKD
(92.5%). Diabetes, hypertension and cardiovascular disease became more common
with more advanced CKD. Antihypertensives and LMTs have been prescribed for a
little over 75% and 50% patients, respectively, regardless of their CKD stage.
PCV4
THE OPTIMAL INTERVAL OF FRAMINGHAM RISK SCORE TO DETECT
CARDIOVASULAR DISEASE IN HEALTHY ADULTS: A LARGE COHORT STUDY IN
JAPAN
Takahashi O1, Ohde S2, Deshpande GA2, Fukui T1
1St.Luke’s International Hospital, Tokyo, Japan, 2St.Luke’s Life Science Institute, Tokyo, Japan
OBJECTIVES: The Framingham risk score screening is an important tool to identify
adults’ 10-year risk of cardiovascular disease (CVD), but there are few studies re-
garding the appropriate monitoring interval for re-screening. We aimed to deter-
mine the optimal interval for rechecking the Framingham risk score for healthy
adults in Japan. METHODS: This was a population-based, retrospective cohort
study from 2005 to 2010 in Tokyo, Japan. In healthy adults with a Framingham risk
score of 20%, no prior CVD, and taking no hypertension or hyperlipidemia med-
ications at baseline, we calculated the Framingham risk score annually for 4 years.
We estimated the optimal interval of screening when the cumulative incidence of
CVD or 20% of Framingham risk scores surpassed 10%. RESULTS: At baseline,
13,758 individuals (53% female) with a mean age of 48 years old (SD: 10 years, range:
30 to 73), had a mean total cholesterol level of 204 mg/dl (SD: 33 mg/dl), and mean
systolic blood pressure of 116 mmHg (SD: 16 mmHg). The prevalence of diabetes
mellitus at baseline was 1.9%. The mean baseline Framingham risk score was 5.3%
(range: 0.3 – 19%). For those with baseline Framingham risk scores of  10 %, 10 –
15%, and  15%, cumulative incidences were 0.2%, 1.6%, and 16.8% at 1 year and
0.8%, 11.5%, and 43.6% at 3 years, respectively. CONCLUSIONS: In those with
Framingham risk scores 20% at baseline, the optimal interval for re-screening
should be more than 3 years for those with risk scores10%, 2 years for those with
risk scores of 10-15%, and yearly for those with baseline scores of 15 %.
PCV5
COMPARISON OF ATRIAL MEASUREMENTS AND ESTIMATIONS OF
TRANSMITRAL REGURGITATION USING THREE-DIMENSIONAL AND
CONVENTIONAL ECHOCARDIOGRAPHY IN DOGS
Poulsen Nautrup B1, Schultheiss S2, Poulsen Nautrup C2
1EAH Consulting, Juelich, Germany, 2Ludwig-Maximilians-University Munich, Munich, Germany
OBJECTIVES: Cardiac volume measurements using three-dimensional echocardi-
ography (3DE) have shown to deliver comparable results to magnetic resonance
imaging (MRI). In a previous investigation, volume measurements of the canine left
ventricle using 3DE was compared to conventional volume calculations by two-
dimensional echocardiography (2DE) and M-Mode, revealing increasingly deviat-
ing results with conventional methods in the mentioned sequence. The aim of this
study was to compare measurements of the left atrium and estimations of trans-
mitral regurgitation using 3DE and 2DE in unsedated dogs. METHODS: Measure-
ments of the left atrium were performed in 42 healthy dogs (beagles and dachs-
hunds), using conventional linear, planimetric and volume calculations with 2DE,
and volume measurements with 3DE. Agreement between methods was analyzed
using Spearman’s rank correlation, intraclass correlation coefficient, and Bland-
Altman plot. Additionally, 20 dogs suffering from mitral valve insufficiency (CHIEF
grades C2 and C3) were recruited for the estimation of transmitral regurgitation,
which was approximated from 2 or 3 planes using 2DE (conventional approach),
and from a live x-plane image using 3DE. RESULTS: Compared to 3DE semi-auto-
matic volume measurements of the left atrium, volume calculations performed
with 2DE (methods of discs, Simpson’s rule) underestimated volumes with devia-
tions being predictable for the respective dog sizes; whereas conventional linear
and planimetric measurements allowed the most rapid investigation, but results
deviated in some dogs unpredictably from those obtained with 3DE. Estimating the
transmitral regurgitation using conventional 2DE was time-consuming and re-
quired replacements of the dogs during investigation, lowering compliance in the
canine cardiac patients, whereas 3DE allowed accurate and more rapid evaluations
without the necessity of replacing the dogs. CONCLUSIONS: Volume measure-
ments of the left atrium are most accurate using 3DE. Additionally 3DE facilitates
the estimation of transmitral regurgitation in dogs, increasing compliance with the
investigation. However, further clinical and economic evaluations are needed in
veterinary cardiology.
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COMPARISON RIVAROXABAN WITH OTHER ANTITHROMBOTIC AGENTS:
EFFECTIVENESS AND SAFETY OF PROPHYLACTIC ANTITHROMBOTIC AGENTS
AFTER MAJOR ORTHOPEDIC SURGERIES IN TAIWAN
Chang WY1, Hsu HC2, Wu CH2, Chen PS2, Wu MT1
1Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan, 2Taipei Medical University,
Taipei, Taiwan
OBJECTIVES: To evaluate the current utilization, effectiveness, and safety of anti-
thrombotics for preventing deep vein thrombosis (DVT) after major orthopedic
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surgeries. METHODS: This one-year retrospective cohort study was conducted at a
medical center in Taiwan from January 1st to December 31th in 2011. Adult patients
(above 18 years) who had undergone total hip replacement or total knee replace-
ment were identified by inpatient electronic database. Medical records were re-
viewed from the surgery day to at least three months post-operation for collecting
demographic details and DVT-related clinical symptoms as the surrogate of effec-
tiveness. Demographic and prescribing patterns of antithrombotics were assessed
by descriptive statistic. Relative risk (RR) was calculated with 95% confidence in-
terval (95%CI). RESULTS: Medical records of 212 patients (66.98% women) were
reviewed. A total of 81 patients (38.21%) received rivaroxaban, 37 patients (17.45 %)
received aspirin, 7 patients (3.30%) received warfarin, and 45 (21.22%) patients
received no antithrombotics and antiplatlets. There was no stroke case in aspirin,
warfarin, and aspirin/rivaroxaben combination group. Compared to other anti-
thrombotics, rivaroxaben was associated with higher RR for stroke (RR 1.11, 95%CI
0.10-11.92), but lower RR for bleeding (RR 0.83, 95%CI 0.32-2.19). However, aspirin/
rivaroxaben combination group showed an increase in bleeding events (RR 1.87,
95%CI 0.46-7.70). CONCLUSIONS: Treatment with aspirin or warfarin seems effec-
tively reduce the risk of stroke. Aspirin/rivaroxaben combination may increase
bleeding events. Further studies are needed to explore the effectiveness and safety
of antithrombotics using a longitudinal data source with sufficient patients’ char-
acteristic data.
PCV7
A MIXED TREATMENT COMPARISON (MTC) TO COMPARE THE EFFICACY OF
ANTI-THROMBOTIC AGENTS IN THE PREVENTION OF STROKE AND SYSTEMIC
EMBOLISM (SE) IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION
(NVAF)
Edwards SJ, Hamilton V, Nherera L, Trevor N, Barton S
BMJ Group, London, UK
This research was conducted during a review of the manufacturer’s submission
(MS) to the NICE Single Technology Appraisal programme for the oral direct factor
Xa inhibitor, rivaroxaban. OBJECTIVES: New anti-thrombotic drugs are available
for prevention of stroke in patients with NVAF but evidence on their clinical effec-
tiveness compared with existing treatments is limited. This research compared the
clinical effectiveness of rivaroxaban, dabigatran etexilate (dabigatran), aspirin and
adjusted standard dose warfarin (warfarin) in people with NVAF. METHODS: Ran-
domised controlled trials (RCTs) for inclusion were identified using the MS for
rivaroxaban, and 2 similar reports for dabigatran; inclusion was validated using
published systematic reviews. RCTs were assessed for comparability based on pa-
tient population, disease severity, and treatments received. A Bayesian MTC was
conducted, and fixed and random effects models were explored. Consistency was
assessed via pair-wise meta-analysis for each treatment versus warfarin. Odds
ratio (OR) was chosen as the summary statistic. RESULTS: The network of 8 RCTs
formed a “radiating star”. The fixed effects model was the best-fitting model. There
was reasonable agreement between the number of unconstrained data points,
residual deviance and pair-wise results, suggesting a coherent network. Statisti-
cally significant results compared with warfarin were: reduction in ischaemic
stroke with dabigatran (OR 0.78; 95% Credible Interval [95%CrI]: 0.60–1.00); reduc-
tion in SE with rivaroxaban (OR 0.24; 95%CrI: 0.07–0.54); reduction in minor ex-
tracranial bleeds with dabigatran (OR 0.88; 95%CrI: 0.82–0.96) and aspirin (OR 0.57;
95%CrI: 0.33–0.91); reduction in intracranial bleeds with dabigatran (OR 0.41;
95%CrI: 0.27–0.60) and rivaroxaban (OR 0.66; 95%CrI: 0.46–0.92); increase in myo-
cardial infarction with dabigatran (OR 1.43; 95%CrI: 1.02–1.97); and increase in dis-
continuations with dabigatran (OR 1.36; 95%CrI: 1.24–1.48). CONCLUSIONS: This
research suggests dabigatran and rivaroxaban may offer different clinical benefits
and harms in patients with NVAF compared with warfarin.
PCV8
ASSESSMENT OF 30-DAY REHOSPITALIZATION FOR ACUTE MYOCARDIAL
INFARCTION IN PATIENTS WITH ACUTE CORONARY SYNDROME WHO
RECEIVED PERCUTANEOUS CORONARY INTERVENTION: A COMPARATIVE
EFFECTIVENESS STUDY OF CLOPIDOGREL AND PRASUGREL
Bae JP1, Faries DE1, Ernst FR2, Lipkin C2, Zhao Z1, Moretz C2
1Eli Lilly and Company, Indianapolis, IN, USA, 2Premier Healthcare Alliance, Charlotte, NC, USA
OBJECTIVES: A 30-day rehospitalization rate for acute myocardial infarction (AMI)
following hospital discharge among patients with acute coronary syndrome (ACS)
who have received percutaneous coronary intervention (PCI) has been adopted as
a hospital quality and performance measure. This study sought to compare 30- and
90-day AMI-related rehospitalization rates between ACS-PCI patients receiving
clopidogrel versus those receiving prasugrel. METHODS: The study endpoint was
pre-specified, and analysis was done under blinding. Using a large geographically
diverse US database maintained by PREMIER, the study analyzed AMI-related re-
hospitalizations among ACS-PCI patients receiving either clopidogrel or prasugrel
between July 2009 and June 2011. Analysis included patients treated with prasugrel
who were on-label and clopidogrel-treated patients who would have been eligible
for prasugrel treatment per the label. Treatment differences in rehospitalization
rate at 30 and 90 days were analyzed. Unadjusted comparisons used chi-square
tests. Multivariate logistic regression analyses adjusted for baseline patient differ-
ences using propensity score stratification. RESULTS: Data were available for
83,576 patients, of which 74,163 received clopidogrel and 9,403 received prasugrel.
For clopidogrel and prasugrel, respectively, the observed AMI-related rehospital-
ization rates were 4.74% and 3.85% at 30 days (P0.0001) and 6.27% and 5.13% at 90
days (P0.0001). Prasugrel was associated with approximately 10% lower odds of
AMI-related rehospitalization (Odds ratio0.892 at 30 days [95% CI: 0.798-0.998];
Odds ratio0.901 at 90 days [95% CI: 0.817-0.994]). CONCLUSIONS: Compared to
clopidogrel-treated patients, prasugrel- treated patients experienced fewer rehos-
pitalizations for AMI at 30 days and 90 days following ACS-PCI discharge. Similar
results were obtained after adjusting for patient demographics and clinical char-
acteristics. The potential for unmeasured confounder bias is a limitation in this
real-world observational research.
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ASSOCIATION BETWEEN PERSISTENCE WITH STATINS AND REDUCTION OF
LOW DENSITY LIPOPROTEIN CHOLESTEROL: ANALYSIS OF REAL-LIFE DATA
FROM COMMUNITY SETTINGS
Shalev V, Goldstein I, Porath A, Chodick G
Maccabi Healthcare Services, Tel Aviv, Israel
OBJECTIVES: To quantify the association between persistence with statins and low
density lipoprotein cholesterol (LDL-C) levels using real-life data in community
settings.METHODS:A retrospective population-based cohort study was conducted
among eligible 87,219 primary-prevention and 15,139 secondary-prevention pa-
tients who are members of a large health maintenance organization and initiated
statins therapy between 1998 and 2008. Baseline and follow-up LDL levels were
collected from three months prior to the date of first dispensed statins (index date)
to six months afterwards. Persistence was assessed by proportion of follow-up
days covered (PDC) with statins. RESULTS: Over the study follow-up period, there
were significant (P 0.001) reductions in LDL-C levels of 54, 33 and 13 mg/dl among
highly persistent (PDC80%), poorly persistent (34%PDC80%), and non-per-
sistent statins users (PDC33%), respectively. In a multivariable model, high per-
sistence with statins therapy was associated with a 27% and 25% decrement in
LDL-C level among primary and secondary prevention cohorts, respectively. Sim-
ilarly, a higher proportion of the persistent statins users reached target LDL-C level
within the study follow-up period (80% and 58% among primary and secondary
prevention cohorts, compared to only 28% and 17%, among non-persistent
patients). CONCLUSIONS: In this observational population-based study, calculated
PDC with statins during study follow-up was strongly associated with drug effect of
LDL-C reduction. The results agree with previous estimates of statins efficacy from
randomized clinical trials, supporting the validity of using PDC methods as a mea-
sure of drug exposure.
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COST-EFFECTIVENESS OF EXTENDED DURATION THROMBOPROPHYLAXIS
AFTER SURGICAL DISCHARGE
Iannuzzi JC, Rickles AS, Fleming FJ, Monson JR, Noyes K
University of Rochester School of Medicine and Dentistry, Rochester, NY, USA
OBJECTIVES: Post-discharge thromboprophylaxis is the practice of prescribing an-
tithrombotic therapy for 21 days after discharge, commonly used in surgical pa-
tients who are at high risk for venothromboembolism (VTE). While randomized
controlled trials have demonstrated a risk reduction for VTE after major general
surgery, the incidence rate where it is cost effective has not been established.
Previous cost analyses have not included an effectiveness component, and have
not reported a threshold VTE incidence rate to help answer for which procedures it
should be implemented. This study sought to determine the VTE incidence thresh-
old for the cost-effectiveness of low molecular weight heparin for 4 weeks after
surgery as compared to inpatient prophylaxis only. METHODS: A cost-effective-
ness decision tree was created using TreeAge. Assigned probabilities were derived
from published literature. The decision point compared extended duration throm-
boprophylaxis with low molecular weight heparin for 21 days after discharge to
inpatient-prophylaxis alone, with base case assumptions based on an abdominal
oncologic resection without complications in a 45 year-old male. The end points
were pulmonary embolism or deep vein thrombosis with attendant costs and as-
signed effectiveness evaluated by QALY. Willingness to pay was set at $50,000/
QALY. Sensitivity analyses were performed to assess uncertainty within the model,
with particular interest in the threshold for cost-effectiveness based on VTE
incidence. RESULTS: Given base case assumptions with VTE probability of 4%,
extended duration thromboprophylaxis had an incremental cost effectiveness ra-
tio of $8123/QALY, which was considered cost-effective. The results were robust to
sensitivity analysis with the highest uncertainty associated with VTE incidence
and medication cost. The threshold for the relative cost-effectiveness was a VTE
incidence exceeding 2.53%. CONCLUSIONS: Given the base case assumptions, ex-
tended prophylaxis is more cost effective than inpatient prophylaxis alone, and the
threshold for its use should be cases where the estimated VTE risk exceeds 2.53%.
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INDIRECT TREATMENT COMPARISON (ITC) OF NOVEL ORAL ANTICOAGULANTS
FOR THE PREVENTION OF THROMBOEMBOLIC EVENTS IN PATIENTS WITH
ATRIAL FIBRILLATION
Pechlivanoglou P1, Le HH1, Engelfriet PM2, Redekop WK3, Postma MJ1
1University of Groningen, Groningen, The Netherlands, 2National Institute for Public Health and
the Environment, Bilthoven, The Netherlands, 3Erasmus University Rotterdam, Rotterdam, The
Netherlands
OBJECTIVES: Atrial fibrillation (AF) is associated with an increased stroke risk.
Anticoagulation with vitamin K antagonists (VKAs) such as warfarin has been the
recommended prophylactic strategy for AF patients but suffers from shortcomings,
including a need for regular monitoring. Novel oral anticoagulants (NOACs) were
developed with the advantages of absence of monitoring and improved effective-
ness and safety profiles. While clinical findings look promising, there are no direct
comparisons between these newer agents. Through indirect treatment compari-
sons (ITC), this study assessed the comparative effectiveness of dabigatran (110mg
and 150mg), rivaroxaban, apixaban, and warfarin in the prevention of thromboem-
bolic events among warfarin-eligible AF patients. METHODS: ITC models were
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